Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study.

Szczegóły
Abstrakt

Tytuł:: Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study.
Autorzy:: Abdel-Rahman O; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton.
Pham TM; Surveillance and Reporting, Cancer Research and Analytics, Cancer Care Alberta.
Pokhrel A; System Performance and Innovation, Emergency Medical Services (EMS), Alberta Health Services.
Ruether D; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Sawyer MB; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton.
Źródło:: American journal of clinical oncology [Am J Clin Oncol] 2022 May 01; Vol. 45 (5), pp. 208-214. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York, N.Y. : Masson Pub. USA, c1982-
MeSH Terms:: Neuroendocrine Tumors*/therapy
Alberta/epidemiology ; Cohort Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Prognosis ; Proportional Hazards Models ; Retrospective Studies
References:: Fazio N, Abdel-Rahman O, Spada F, et al. RAF signaling in neuroendocrine neoplasms: from bench to bedside. Cancer Treat Rev. 2014;40:974–979.
Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153–171.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann Oncol. 2020;31:844–860.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
Mariotto AB, Noone A-M, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014:145–186.
Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958;8:699–712.
Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol. 1972;34:187–220.
The Stratified Cox Procedure. Survival Analysis. Statistics for Biology and Health. New York, NY: Springer; 2005. Available at: https://doi.org/10.1007/0-387-29150-4_5 . (PMID: 10.1007/0-387-29150-4_5)
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–977.
Abdel-Rahman O, Fazio N. Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study. Pancreas. 2021;50:727–731.
Man D, Wu J, Shen Z, et al. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–5638.
Estrella JS, Broaddus RR, Mathews A, et al. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014;138:1027–1036.
Estrella JS, Ma LT, Milton DR, et al. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014;43:996–1002.
Gosain R, Ball S, Rana N, et al. Geographic and demographic features of neuroendocrine tumors in the United States of America: a population-based study. Cancer. 2020;126:792–799.
Hallet J, Law CH, Karanicolas PJ, et al. Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases. Cancer. 2015;121:2214–2221.
Abdel-Rahman O, Tang PA, Koski S. Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study. Int J Colorectal Dis. 2021;36:1905–1913.
Abdel-Rahman O, Koski S, Mulder K. Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. Int J Colorectal Dis. 2021;36:493–499.
Entry Date(s):: Date Created: 20220406 Date Completed: 20220425 Latest Revision: 20230903
Update Code:: 20240105
DOI:: 10.1097/COC.0000000000000906
PMID:: 35383575
: Czasopismo naukowe

Background: The past 2 decades have observed a number of advances in therapeutic approaches to patients with neuroendocrine neoplasms (NENs). This study aims to assess whether survival outcomes have changed among patients with NENs over the past 15 years, in a real-world, population-based study.
Materials and Methods: We accessed administrative databases within the province of Alberta, Canada, and we reviewed patients with invasive NENs diagnosed 2004 to 2019. Patients were classified according to the year of diagnosis into 3 groups: 2004 to 2008; 2009 to 2013; and 2014 to 2019. Kaplan-Meier survival estimates were used to compare overall survival (OS) according to different baseline characteristics (including the year of diagnosis). Multivariable Cox regression modeling was used to examine factors associated with the risk of death in this cohort.
Results: We included a total of 3431 patients in the study cohort. Using multivariable Cox regression analysis, the following factors were associated with worse survival: older age at diagnosis (hazard ratio [HR]: 3.45; 95% CI [confidence interval]: 2.74-4.35), male sex (HR: 1.38; 95% CI: 1.21-1.56), lung primary site (HR for lung vs. appendicular primary: 1.39; 95% CI: 1.01-1.92), Stage 4 disease (HR: 2.80; 95% CI: 2.38-3.30), South zone of the province (HR for South zone vs. Calgary zone: 1.85; 95% CI: 1.49-2.30), and higher comorbidity index (HR for ≥3 vs. 0: 2.66; 95% CI: 2.19-3.24). Although Kaplan-Meier method showed significant difference in OS according to diagnosis period, multivariable regression model showed that the period of diagnosis did not appear to impact OS (HR for diagnosis period 2004 to 2009 vs. 2014 to 2019: 1.04; 95% CI: 0.89-1.22).
Conclusions: Over the study period (2004 to 2019), patients diagnosed during later periods did not appear to experience better OS compared with patients diagnosed at an earlier time.
Competing Interests: O.A.-R: Advisory boards with Ipsen, Lilly, Roche, Bayer, and Eisai. M.B.S.: Advisory boards with Ipsen and Novartis. The remaining authors declare no conflicts of interest.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Informacja